REVLIMID-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG ) today announced that results from a retrospective analysis of patients with International Prognostic Scoring System (IPSS)